National Institutes Of Health
-
Vanderbilt building molecular atlas of colorectal cancer across different stages of disease onset with $5 million National Cancer Institute grant
Colorectal cancer is the second leading cause of cancer-related deaths in the U.S. Ken Lau and Jeffrey Spraggins are creating the first spatially mapped atlas characterizing the progression trajectories of early-onset colorectal cancer versus average-onset CRC as they transition from precancerous lesions to malignant cancers. Read MoreNov. 20, 2024
-
Passion, Perseverance and Synapses: Neuroscientist Richard Sando receives prestigious NIH New Innovator Award
In 2024 the National Institutes of Health awarded Sando a New Innovator Award, part of their High-Risk, High-Reward Research program. This award, which provides $1,500,000 over five years, supports early-career scientists proposing innovative and impactful research that might not get funded in the traditional peer-review process due to its inherent risk. Read MoreOct. 14, 2024
-
Research Snapshot: Protons can tune synaptic signaling by changing the shape of a protein receptor
Research from Teru Nakagawa, professor of molecular physiology and biophysics, describes intricacies of normal brain function with implications for our understanding of brain injury and recovery: A decrease in pH can modify a neurotransmitter receptor’s structure, thereby modulating its location and kinetics. Read MoreAug. 13, 2024
-
NIH training program in engineering and diabetes competitively renewed for another five years
The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health has renewed a five-year grant through the NIH’s flagship T32 institutional training grant program. T32 grants provide funding to support students and postdoctoral trainees working in focused areas of research that advance the NIH mission. Read MoreAug. 2, 2024
-
‘Smarter Every Day’ explores how bacteria move to survive—and make us sick
In a recent episode of Smarter Every Day, YouTube sensation and host Destin Sandlin talks with Vanderbilt Professor Tina Iverson and Senior Research Associate Prashant Singh about bacterial “motors” and how they work in the microorganisms that make us sick. The video racked up more than 1.4 million views in its first day. Read MoreJul. 31, 2024
-
Jeffrey Spraggins named director of Vanderbilt University Mass Spectrometry Research Center
Jeffrey Spraggins, a leading scientist in imaging mass spectrometry, has been named director of the Mass Spectrometry Research Center. The MSRC is a highly collaborative research entity incorporating a wide range of technologies and serving hundreds of users, including partnering with pharmaceutical companies on drug development research. Read MoreJul. 17, 2024
-
New drug candidates targeting blood clots developed through computer-aided drug design
Using computer-aided drug design, the labs of Heidi Hamm, Jens Meiler, and Craig Lindsley generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read MoreJun. 6, 2024
-
Pharmacology, VCAR prioritize diverse funding opportunities to support trainees and faculty
The Vanderbilt School of Medicine Basic Sciences’ pharmacology department and the Vanderbilt Center for Addiction Research hosted a special event on April 22 focused on the importance of funding for diverse trainees and faculty in academic settings. The speakers discussed the various grants to fund underrepresented trainees and faculty at various stages in their career. Read MoreJun. 2, 2024
-
Vanderbilt-discovered cancer killing compound is now available through Boehringer Ingelheim open science portal opnMe
By targeting a notoriously undruggable protein found in many cancers, the discovery of BI-0474 may pave the way for new cancer treatments. Shared on opnMe.com by Boehringer Ingelheim, this innovative molecule is available for global researchers to explore new research avenues. Read MoreMay. 28, 2024
-
Research Snapshot: Understanding protein mutations that affect gene expression
Foundational research from the Hiebert lab reveals genetic targets that can be leveraged to identify therapies that affect lymphoma cell growth. Read MoreMay. 23, 2024